$BioNTech SE(BNTX)$Biontech has more potential than Novavax because it holds the core patents for mRNA techniques. Even if other companies come up with vaccines of their own, if they use mRNA technologies, they have to pay licensing to Biontech and others who hold core patents. End of the day, if you think from business point of view, the companies with core patents can sell their vaccines cheaper, and have a much larger share of the market.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments